Liquidia Corporation (LQDA) fundamentals score
Liquidia is a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases such as pulmonary arterial hypertension (“PAH”) and pulmonary hypertension associated with interstitial lung disease (“PH-ILD”).
Pharmaceutical Preparations · Healthcare · Listed on NASDAQ
Overall: 7.8 out of 10, Good long-term fundamentals
- Growth: 6.3/10
- Profitability: 9.8/10
- Financial health: 9.1/10
- Earnings quality: 5.1/10
- Valuation: 7.6/10
Scores are calculated from Liquidia Corporation’s SEC filings, using the 12 months through 2026-06. Compare it with past big winners, check its flags, and see today’s price against its fundamentals in the full scorecard.
Other Healthcare stocks
- Nurix Therapeutics, Inc. (NRIX): 9.0/10
- Caredx, Inc. (CDNA): 8.9/10
- Dexcom, Inc. (DXCM): 8.8/10
- Exelixis Inc. (EXEL): 8.8/10
- Neurocrine Biosciences Inc. (NBIX): 8.7/10
- Progyny, Inc. (PGNY): 8.6/10
- Healthcare Services Group, Inc. (HCSG): 8.5/10
- Insulet Corporation (PODD): 8.5/10